An in vivo approach was used to correct the ornithine transcarbamylase (OTC) deficiency he suffered from, by injecting a recombinant adenovirus harboring the OTC gene directly into his blood stream. This evidence concerns the gene OTC and ornithine carbamoyltransferase deficiency.